| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5583122 | WARNER CHILCOTT | Pharmaceutical compositions containing geminal diphosphonates |
Dec, 2013
(10 years ago) | |
|
US5583122 (Pediatric) | WARNER CHILCOTT | Pharmaceutical compositions containing geminal diphosphonates |
Jun, 2014
(9 years ago) | |
| US6165513 | WARNER CHILCOTT | Film-coated tablet for improved upper gastrointestinal tract safety |
Jun, 2018
(5 years ago) | |
| US5994329 | WARNER CHILCOTT | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
| US6432932 | WARNER CHILCOTT | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
| US6015801 | WARNER CHILCOTT | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
| US6465443 | WARNER CHILCOTT | Method for inhibiting bone resorption |
Aug, 2018
(5 years ago) | |
|
US6165513 (Pediatric) | WARNER CHILCOTT | Film-coated tablet for improved upper gastrointestinal tract safety |
Dec, 2018
(5 years ago) | |
|
US6432932 (Pediatric) | WARNER CHILCOTT | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
|
US5994329 (Pediatric) | WARNER CHILCOTT | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
|
US6015801 (Pediatric) | WARNER CHILCOTT | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
|
US6465443 (Pediatric) | WARNER CHILCOTT | Method for inhibiting bone resorption |
Feb, 2019
(5 years ago) | |
Actonel With Calcium (Copackaged) is owned by Warner Chilcott.
Actonel With Calcium (Copackaged) contains Calcium Carbonate; Risedronate Sodium.
Actonel With Calcium (Copackaged) has a total of 12 drug patents out of which 12 drug patents have expired.
Expired drug patents of Actonel With Calcium (Copackaged) are:
- US5583122
- US5583122*PED
- US6165513
- US5994329
- US6432932
- US6015801
- US6465443
- US6165513*PED
- US6432932*PED
- US5994329*PED
- US6015801*PED
- US6465443*PED
Actonel With Calcium (Copackaged) was authorised for market use on 12 August, 2005.
Actonel With Calcium (Copackaged) is available in tablet;oral dosage forms.
Actonel With Calcium (Copackaged) can be used as 35 mg orally once a week for prevention of osteoporosis in postmenopausal women; 35 mg orally once a week for treatment of osteoporosis in postmenopausal women, prevention and treatment of osteoporosis.
The generics of Actonel With Calcium (Copackaged) are possible to be released after 14 February, 2019.
Drugs and Companies using CALCIUM CARBONATE; RISEDRONATE SODIUM ingredient
Market Authorisation Date: 12 August, 2005
Treatment: Prevention and treatment of osteoporosis; 35 mg orally once a week for prevention of osteoporosis in postmenopausal women; 35 mg orally once a week for treatment of osteoporosis in postmenopausal wome...
Dosage: TABLET;ORAL
ACTONEL WITH CALCIUM (COPACKAGED) family patents
